Brisbane, Australia, 1 July 2020 — ResApp Health Limited (ASX:RAP), a leading digital health company developing smartphone applications for the diagnosis and management of respiratory disease, and Phenix Health Pty Ltd, Australia’s leading virtual super clinic, are pleased to announce that ResAppDx-EU, the world’s first clinically validated and regulatory-approved respiratory disease diagnostic test, is scheduled to be available on the Phenix Telehealth app on Monday the 6th of July.
Phenix and ResApp signed a software licensing agreement in June to provide ResAppDx-EU in the Phenix Telehealth app. The software licensing agreement is a two-year, non-exclusive agreement, with a per test license fee received by ResApp within the previously targeted range of $5-10. The software integration has been completed and the updated Phenix Telehealth app, which includes the ResAppDx-EU test, has been submitted to the App Store for review and is planned to be released to the public on Monday the 6th of July.
ResAppDx-EU is directly integrated into the Phenix Telehealth app and uses the patient’s own smartphone to record and analyse the patient’s cough sounds. The results are securely sent to their telehealth doctor. ResAppDx-EU does not require the purchase or use of any accessories or additional hardware devices.
“The launch of our virtual respiratory clinic means we are able to offer patients who have respiratory symptoms a complete care experience,” said Gillian Alexis, CEO and founder of Phenix. “With ResApp’s technology now integrated into the Phenix Teleheath app, our doctors can remotely assess patients with confidence, perform a high quality video consultation and even deliver medications to their patient’s home.”
“We’re excited to be launching ResAppDx-EU Australia-wide through Phenix’s virtual respiratory clinics,” said Tony Keating, CEO and Managing Director of ResApp. “After the Australian government approved Medicare rebates for telehealth consultations, adoption of telehealth in Australia has accelerated. The combination of Phenix’s virtual consultation platform and ResAppDx-EU enables clinicians to accurately assess patients with respiratory symptoms, delivering the high levels of care that patients expect.”
About ResApp Health Limited
ResApp Health Limited (ASX: RAP) is a leading digital health company developing smartphone applications for the diagnosis and management of the respiratory disease. ResApp’s machine learning algorithms use sound to diagnose and measure the severity of respiratory conditions without the need for additional accessories or hardware. ResApp’s regulatory-approved and clinically validated products include ResAppDx-EU, a smartphone-based acute respiratory disease diagnostic test for use in telehealth, emergency department and primary care settings; and SleepCheck, an at-home sleep apnoea screening app for consumers to self-assess their risk of sleep apnoea. Both products are CE Marked in Europe and TGA approved in Australia. For more information, please visit www.resapphealth.com.au.
About Phenix Health Pty Ltd
Phenix Health Pty Ltd is an integrative medical tech company founded in 2015 as a spin-off from our Australia-wide after-hours home visit doctor service where it was evidenced that large sectors of the population were not able to access adequate healthcare services. Phenix worked towards developing and refining our mobile technology, remote patient monitoring and telehealth service that assists connect both health professionals to their patient. Our mobile technology includes many clinical operational features providing a powerful collaborative tool for health care providers in: clinic, aged care facilities, emergency services, hospitals and remote and mobile settings. Phenix Health solves the disconnect between vertical digital health silos. Our team has come together through years of experience in developing and operating 24/7 health care services across metro and regional. For more information, please visit www.phenixhealth.com.au.
Contacts for ResApp Health
Dr Tony Keating
CEO and Managing Director
+61 430 180 659
VP, Corporate Affairs
+61 412 281 780
ResApp Health Limited
ABN 51 094 468 318
Level 12, 100 Creek St, Brisbane, QLD 4000
© 2021 ResApp Health Limited. All rights reserved. US Patent No. 10,098,569, Australian Patent No. 2013239327, Japanese Patent No. 6,435,257, South Korean Patent No. 1020812410000 and Patents Pending. ResApp Health®, the ResApp Health logo and ResAppDx® are registered trademarks of ResApp Health Limited in the United States and other countries. ResAppDx is not available for sale in the United States.